Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.
van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ, Trimbos JB. van Driel WJ, et al. Among authors: van dam pa, van rossum ab. Eur J Cancer. 1999 Jun;35(6):946-52. doi: 10.1016/s0959-8049(99)00048-9. Eur J Cancer. 1999. PMID: 10533477 Clinical Trial.
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).
Green JA, Berns EM, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RH, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg ME; EORTC Gynaecological Cancer Group. Green JA, et al. Eur J Cancer. 2006 Oct;42(15):2539-48. doi: 10.1016/j.ejca.2006.06.015. Epub 2006 Sep 11. Eur J Cancer. 2006. PMID: 16965910 Clinical Trial.
No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham M, van Dam P, Vuylsteke P, Bastings J, Kruitwagen RFPM, Lambrechts S, Olde Damink SWM, Rensen SS, Van Gorp T, Sonke GS, van Driel WJ. Ubachs J, et al. Gynecol Oncol. 2020 Dec;159(3):706-711. doi: 10.1016/j.ygyno.2020.09.042. Epub 2020 Oct 2. Gynecol Oncol. 2020. PMID: 33019981
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC. Koole SN, et al. Int J Cancer. 2022 Oct 15;151(8):1394-1404. doi: 10.1002/ijc.34124. Epub 2022 Jun 4. Int J Cancer. 2022. PMID: 35583992 Free article. Clinical Trial.
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H. Tuyaerts S, et al. Among authors: van dam pa, van nuffel amt. BMC Cancer. 2019 May 28;19(1):506. doi: 10.1186/s12885-019-5676-3. BMC Cancer. 2019. PMID: 31138229 Free PMC article. Clinical Trial.
Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
van Dam P, Huizing M, Roelant E, Hotterbeekx A, De Winter FHR, Kumar-Singh S, Moons P, Amajoud Z, Vulsteke C, Croes L, Janssens A, Berneman Z, Prenen H, Meuris L, Vanden Berghe W, Smits E, Peeters M. van Dam P, et al. Eur J Cancer. 2021 May;148:328-339. doi: 10.1016/j.ejca.2021.02.024. Epub 2021 Feb 27. Eur J Cancer. 2021. PMID: 33773276 Free PMC article.
192 results